Veledimex
As of the edition of 20 October 2026, Veledimex is a small molecule: stopped in 2022; acts on CREBBP.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Small molecule
- Registered trials
- 9, 4 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Veledimex.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CREBBP | CREB-binding protein | Q92793 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 5 | 1 | 0 | 4 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Alaunos Therapeutics | Lead sponsor of trials | 2009 to now |
| Castle Creek Biosciences | Lead sponsor of trials | 2019 to now |